---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-044667"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2022-12-07T23:59:59+00:00"
generated_at: "2026-06-21T08:03:06.350300+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics prices public offering of 20.98M shares at $2.86 for $60M gross proceeds

## Summary
- Offering of 20,979,020 shares at $2.86/share; gross proceeds ~$60M before expenses.
- Underwriters granted 30-day option to purchase up to 3,146,853 additional shares at same price.
- Closing expected on or about December 9, 2022, subject to customary conditions.
- Net proceeds to accelerate commercialization, production, plasma center buildout, FDA approvals, and R&D.
- Joint book-running managers: Raymond James, Cantor Fitzgerald, and Mizuho Securities.

## SEC filing metadata
- accession: 0001140361-22-044667
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2022-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044667/0001140361-22-044667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044667/ny20006122x3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-044667
- JSON: https://secwatch.observer/filing/0001140361-22-044667.json
- Plain text: https://secwatch.observer/filing/0001140361-22-044667.txt

## Key facts
- Material Agreements
  ADMA BIOLOGICS, INC. entered into Underwriting Agreement with Raymond James & Associates, Inc., acting as representative of the several underwriters named therein valued at approximately $60 million (effective 2022-12-07).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Raymond James & Associates, Inc., acting as representative of the several underwriters named therein
  - Value: approximately $60 million
  - Effective: 2022-12-07
  source text: On December 7, 2022, ADMA Biologics, Inc., a Delaware corporation (the “Company”) priced its previously announced underwritten public offering pursuant to which the Company has agreed to issue and sell an aggregate of 20,979,020 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $2.86 per share, for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the offering (the “Offering”). Pursuant to the terms of the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between the Company and Raymond James & Associates, Inc., acting as representative of the several underwriters named therein (the “Underwriters”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036122044667/0001140361-22-044667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.